The M-ERA.NET Call 2013 – http://www.m-era.net
The M-ERA.NET Call 2013 opened on the 10th July 2013. 32 funding agencies from 23 European countries as well as Taiwan and Russia participate in this joint call, with a total available public funding of around 33 million Euro.
Please find a detailed matrix with the conditions of your Country participation http://www.m-era.net/participating-countries-call-2013. Pay attention pls, that some Countries can participate only in defined thematics.
Funding will be offered to innovative projects focusing on:
· Integrated Computational Materials Engineering
· Interfaces, Surfaces and Coatings
· Composite Technology
· Materials for Health
· Materials for Sustainable and Affordable Low Carbon Energy Technologies
Call announcement: http://www.m-era.net/sites/default/files/2013-call-announcement%20M-ERA-NET-100713.pdf
Guide for proposers: http://www.m-era.net/sites/default/files/2013-GuideForProposers-final_0.pdf
Mandatory pre-proposal form: http://www.m-era.net/joint-call-2013
Full proposal form (not available yet)
Deadline for 1st stage of proposal submission: 30 October 2013
Deadline for final stage of proposal submission: 25 March 2014
List of 27 eligible Countries: http://www.m-era.net/participating-countries-call-2013
A minimum of 3 partners from two different countries participating in the M-ERA.NET call
Approx. funding on 1 Partner: 200 000 euro (2 years)
SUBMIT mandatory pre-proposal (deadline 30 October 2013, 12:00 noon Brussels time) via the on-line system: https://www.vdivde-it.de/meranet-submission/submission/call-2013
Russian companies already searching for partners:
Also I represent you a Russian company partner search on M-ERA (not only) in the field of «Materials for health», below:
PS: Manufacturing technology of smart drugs to treat severe wounds: purulent, gunshot and diabetic foot.
Manufacturing technology of smart drugs to treat severe wounds: purulent, gunshot and diabetic foot. Technology of production of ointment with effect of aimed transportation (bio-interface effect) and retention of antibiotics to infected tissues, an increase in the local concentration of drug molecules. An additional function of transport nanoparticles is to contribute to the restoration of impaired matrix of connective tissue in the affected area.
Final Product of the Project:
Drug ointment (20g, 100g, 500g) and ointment bandages (10×20 cm) to treat severe wounds: purulent, gunshot and diabetic foot.
Type of partner sought:
- continue development and application field expansion of the technology of the active substance deliver by use of bio-interface effect,
- pass necessary steps to access the markets of other countries,
- organize production in other countries
Contribution to the project:
Company has its own industrial and research facilities for the production of active pharmaceutical substance for use in the manufacture of medical ointment bandages and drug ointment. There is a range of sources of raw materials, as nanoparticles, antibiotics, polyethylglycols. All materials and equipment have all necessary permitting documents and certificates of compliance for the right of use for the production of medical products.
FYI – Russian company is eligible to be the Consortium Coordinator.
Pls pay attention that not all Regions in various Countries can receive the funding (pls check the eligible Regions).
Below, you can find the detail information about all ERA.NET Program calls, where your Country can take a part.
Please fill in the attachment if interested. Partner search – template